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Summary
Objectives: To determine whether cartilage biopsies from specific regions of osteoarthritic knee joints differ in susceptibility to the degradative
effects of the amounts of interleukin-1 (IL-1; 1–10 pg/ml) found in osteoarthritic joints. To establish whether biopsies are sensitive to the
effects of either IL-1 or TNF or both catabolic cytokines.
Methods: Cartilage from specified regions of 22 osteoarthritic knee joints was examined. Biopsies were incubated for 14 days without or with
IL-1 or TNF at physiological concentrations and GAG release into supernatants assessed.
Results: Variation was observed in susceptibility to the effects of 1–10 pg/ml IL-1 in biopsies from different sites within the same joints and
the same site in different joints. The number of regions responding to the cytokine increased significantly (P<0.0063, Chi square test) with
concentration: only 10% (2/21) of all regions tested were susceptible to the effects of 1 pg/ml IL-1, whereas 45% (9/20) were susceptible
to the effects of 5 pg/ml and 56% (10/18) to the effects of 10 pg/ml IL-1. Significantly fewer regions (4%, 2/47) responded to both IL-1 and
TNF (P<0.047, Chi square test); biopsies from some patients responded to neither cytokine.
Conclusions: IL-1, at the low concentrations detected in joints, can degrade cartilage from susceptible locations. Susceptibility of some
cartilage biopsies to the effects of either IL-1 and TNF, but not both, suggests the signalling receptors for the two major catabolic cytokines
are not usually expressed concurrently. The fact that some biopsies respond to neither cytokine suggests that in some patients the local
concentration of inhibitors may be high or that other catabolic stimuli predominate. These results could have important implications for
pharmacological intervention strategies. © 2002 OsteoArthritis Research Society International
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Recent advances are beginning to explain how focal loss of
cartilage, characteristic of osteoarthritis (OA), may occur. It
is well established that the catabolic cytokine, IL-1, con-
tributes to inflammatory processes in both animal and
human joints and can degrade animal and human cartilage
in vitro. However, human cartilage is less sensitive to IL-1
than animal cartilage1,2. It therefore remains uncertain
whether this cytokine contributes to the process leading to
loss of cartilage from specified regions of the joint in OA.
Loss of cartilage matrix can result from chondrocyte pro-
duction of enzymes in response to catabolic cytokines3. In
support of this contention, both stromelysin and colla-
genase4, proteoglycan fragments5, denatured collagen6,
IL-1 and TNF4,7 are all detected in osteoarthritic synovial
fluids. Cultured osteoarthritic synovium produces higher
concentrations of IL-1 and TNF than normal synovium8,
which may partially be explained by the fact that osteo-
arthritic synovium contains a higher proportion of264IL-1 secreting cells than normal synovium9. In addition,
osteoarthritic synovial fluids and supernatants from cul-
tured osteoarthritic synovia can both significantly enhance
glycosaminoglycans (GAG) release from cartilage biopsies
(Westacott, unpublished observations). However, for carti-
lage to degrade at specific locations, factors other than the
presence of sufficient cytokine are necessary. It is known
that cartilage from osteoarthritic joints is more sensitive to
the effects of relatively high, non-physiological, concen-
trations of IL-110, and TNF11 than non-arthritic cartilage
and that chondrocyte receptors for the two cytokines are
up-regulated in osteoarthritic cartilage12,13. Thus, focal loss
of cartilage could be due to differences in chondrocyte
sensitivity to the lower physiological concentrations of
cytokine found at specific locations in osteoarthritic joints.
Recently, we demonstrated that regional variation in the
susceptibility of cartilage from specific regions of osteo-
arthritic joints to the effects of 10 ng/ml TNF was
directly related to the number of TNF-receptor (R) type I
(TNF-RI)14. These results suggest a rationale for focal loss
of cartilage in that in the presence of sufficient TNF; only
those regions expressing high numbers of TNF-RI will be
sensitive to its effects. Subsequent experiments showed
similar regional variation in susceptibility to the lower con-
centrations of TNF (0.25–5 ng/ml) likely to be produced in
some osteoarthritic joints15. However, it remains to be
determined whether regional differences exist in the sus-
ceptibility of osteoarthritic cartilage to the effects of IL-1,
particularly the low concentrations (<20 pg/ml) detected in
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whether cartilage biopsies from sites that respond to TNF
also respond to IL-1 or only respond to one of the two
cytokines.CARTILAGE PREPARATION
Cartilage was obtained less then 2 h post-operatively
from specific anatomical regions of knee joints (Fig. 1) of
patients (N=22, age 70.3±10.8 (range 42–86) years, eight
males, 12 females), who fulfilled the ACR criteria for OA,
undergoing surgery for total knee replacement. Details of
joint damage were recorded diagrammatically. Cartilage
was damaged predominantly on the medial aspect of 17
knees, on the lateral aspect of 3 knees and on both
medial and lateral aspects of two knees. Full-depth macro-
scopically normal cartilage slices were removed, where
available, using a scalpel, and washed twice in sterile
phosphate buffered saline (PBS). Semi-circular biopsies
were cut using a biopsy punch (3 mm diameter).CULTURE OF CARTILAGE WITH CYTOKINES
Experiments were performed as described pre-
viously14,15. Briefly, biopsies were made from cartilage
obtained from each of six individual sites on femoral
condyles13. Biopsies (four or more) were selected at ran-
dom from the biopsy pools made from cartilage obtained
from each region. Each biopsy was cut in two. One half of
each biopsy was cultured in 1 ml RPMI supplemented with
5% human AB serum, 2 mM L-Glutamine, 100 U/ml peni-
cillin, 100 g/ml streptomycin and 25 mM HEPES (com-
plete RPMI) with appropriate amounts of cytokine (1, 5 or10 pg IL-1 or 5000 or 500 pg TNF) (test). The corre-
sponding halves were cultured in complete RPMI alone
(control). Biopsies were cultured for 14 days (37°C, 5%
CO2) and the medium changed every 2 days. The culture
supernatants from each time point were collected and
stored at −20°C. At the end of the culture period each
half biopsy was removed, dried in an oven (37°C,
1 week) and weighed.
The effect of specific cytokine at each concentration was
assessed by measuring GAG released into the super-
natant at each time point using the colorimetric method of
Farndale, 198616. The GAG content of the supernatants
were adjusted for dry weight of biopsy and expressed as
micrograms per milligram of cartilage. Cumulative GAG
release from each half biopsy was determined by summat-
ing the concentration of GAG measured at each time point.
Comparison was made between GAG release from
cartilage incubated in the presence of cytokine and GAG
release from cartilage incubated in RPMI alone.STATISTICAL ANALYSIS
The significance of the difference in the amount of GAG
released from replicate half cartilage biopsies incubated
with test cytokine, as compared with that released from the
corresponding control half cultured in RPMI was assessed
using Student’s paired t-test. Chi square test was used to
assess the significance of the difference in regions
responding to different concentrations of IL-1, and the
significance of the difference in regions responding to either
IL-1 or TNF. Fisher’s exact test was used to determine
the significance of the difference in regions responding to
both IL-1 and TNF.Results3
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Fig. 1. Diagram of the right knee joint, showing the different
anatomical regions from which cartilage was obtained. Regions 1,
2 and 3 were located on the lateral femoral condyle, regions 4, 5
and 6 were located on the medial femoral condyle. Regions 1 and
4 were located at the anterior and regions 3 and 6 at the posterior
aspects of the knee joint.SUSCEPTIBILITY OF CARTILAGE TO IL-1 AT LOW
CONCENTRATIONS
To determine the effects on cartilage of the low amounts
of IL-1 detected in supernatants from cultured synovia8,
replicate biopsies of cartilage from specific regions of OA
knee joints were incubated for 14 days with or without 1,
5, or 10 pg/ml IL-1. Differences in GAG release from
biopsies incubated in the presence of cytokine as com-
pared with GAG release from biopsies incubated in RPMI
alone were assessed. The results of the four experiments
performed at each of three cytokine concentrations tested
are summarized in Table I. Regions where cumulative GAG
release from biopsy halves during incubation with cytokine
was significantly greater (P<0.05, Student’s paired t-test)
than corresponding control halves incubated in medium
alone are denoted (+), those regions where cumulative
GAG release during incubation with cytokine was not
significantly different to that from corresponding control
halves incubated in medium alone are denoted (−). The
total number of regions responding to IL-1 increased
significantly (P<0.0063) with cytokine concentration. For
example, whilst only 10% of all biopsies tested were
susceptible to the effects of 1 pg/ml IL-1, 56% were
susceptible to the effects of 10 pg/ml IL-1.Variation was
observed within the same knee joint in susceptibility to the
effects of IL-1. This effect was more marked at the higher
concentrations of cytokine tested where more regions were
responsive. For example, for cartilage stimulated with
10 pg/ml IL-1, biopsies from regions 2 and 3, patient 10,Materials and methods
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from regions 4, 5 and 6 were not. Similarly, for patient 12,
regions 1, 3 and 6 were susceptible to the effects of
cytokine whereas those from region 2 were not. Differences
in response to the effects of cytokine were also seen at the
same site in different knees. Again, this effect was more
marked at the higher cytokine concentrations tested.
Biopsies from region 6, patients 9 and 12, were susceptible
to the effects of IL-1, whereas similar biopsies from the
same region in cartilage from patients 10 and 11 were not.
Although cartilage from region 2 was tested with 10 pg/ml
IL-1 for all four patients, only biopsies from that region for
patients 9 and 10 were susceptible to the effects of the
cytokine. Interestingly, biopsies from all five regions from
patient 9 were susceptible to the effects of 10 pg/ml IL-1,
whereas none of the four regions tested from patient 11
were sensitive to the cytokine. When divided into regions
of origin, more biopsies from the posterior regions (3
and 6) were susceptible to the effects of IL-1 (11/23,
48%). Biopsies from none of the regions of cartilage
obtained from four of 12 patients responded to IL-1 at any
concentration.Table I
Proportion of regions responding to interleukin-1 (IL-1)
IL-1
(pg/ml)
Patient Region
1
Region
2
Region
3
Region
4
Region
5
Region
6
Positive/total*
1 1 − − + ND − − 1/5
2 − − + − − − 1/6
3 ND − − − ND − 0/4
4 − − − − − − 0/6
2/21 (10%)**
5 5 − − + + ND + 3/5
6 − − + − − + 2/6
7 ND ND − − − − 0/4
8 + + ND + − + 4/5
9/20 (45%)
10 9 + + + ND + + 5/5
10 ND + + − − − 2/5
11 − − − ND ND − 0/4
12 + − + ND ND + 3/4
10/18 (56%)
Cartilage was obtained from specific regions on the femoral condyles of twelve osteoarthritic knee joints.
Biopsies, in replicates of four or more, were incubated for 14 days without or with 1, 5, or 10 pg/ml IL-1 and
cumulative GAG release into supernatants during incubation assessed. Comparison was made between GAG
release from biopsies incubated in the presence of IL-1 and that released from biopsies incubated in medium
alone. (+) denotes regions where cumulative GAG release from biopsy halves during incubation with cytokine
was significantly greater (P<0.05, Student’s t-test) than corresponding control halves incubated in medium alone,
(−) denotes regions where cumulative GAG release during incubation with cytokine was not significantly different
to that from corresponding control halves incubated in medium alone. ND (not done) denotes regions for which
insufficient cartilage was available to make replicate biopsies. *Denotes the number of regions responding to
IL-1/total number of regions examined. **Significantly fewer regions (P<0.0063, Chi square test) responded to
1pg/ml IL-1.SUSCEPTIBILITY OF BIOPSIES TO THE EFFECTS OF IL-1 OR TNF
Previous work shows regional variation in susceptibility
to the effects of TNF11,13. To determine whether cartilage
from specific regions is sensitive to either one or both
catabolic cytokines, replicate biopsies obtained from the
same regions of the same knee joints were incubated with
either IL-1 or TNF. Biopsy halves made from cartilage
obtained from specific regions on the femoral condyles of
five knee joints were incubated for 14 days with either
10 pg/ml IL-1 or 500 pg/ml TNF and the corresponding
halves incubated in RPMI alone (Regime A). GAG releaseinto the supernatants was assessed and the results sum-
marized in Table II. Differences in susceptibility to cytokines
were apparent within the same knee joint. For example,
biopsies from region 1 in cartilage from the knee joint of
patient 14 were susceptible to the effects of 10 pg/ml IL-1,
but not 500 pg/ml TNF. Similarly, biopsies from regions 3
and 6 in cartilage obtained from patient 17 were responsive
to IL-1, but not TNF. Differences were also apparent at
the same site in different knees. For example, biopsies from
region 2, patient 16, were susceptible to the effects of
IL-1, but not TNF, while none of the biopsies from that
region in the other four patients was susceptible to the
effects of either cytokine. In all, six of the 23 regions (26%)
available on five knees were susceptible to the effects of
10 pg/ml IL-1. By contrast, biopsies from only one of the
same 23 regions were susceptible to the effects of 500 pg/
ml TNF. Only biopsies from one region, region 3 on the
anterior aspect of the joint, were susceptible to the effects
of both IL-1 and TNF.
We showed previously that the number of regions
responding to TNF rises with concentration15. In order to
increase the chances of detecting biopsies that responded
to both cytokines, we next performed similar experiments
using larger amounts of TNF. Replicate biopsies obtained
from a further five knee joints were incubated for 14 days
with either 10 pg/ml IL-1 or 5000 pg/ml TNF (Regime B).
GAG release into the supernatants was assessed and the
results are summarized in Table II. Again, variation in
susceptibility to IL-1 was apparent in cartilage from differ-
ent regions of the same knee; similar variation was also
apparent in susceptibility within the same knee to the
higher amount of TNF. For example, biopsies from region
5, patient 18, were susceptible to the effects of IL-1, but
not TNF. Conversely, biopsies from region 4 of the same
patient were susceptible to the effects of TNF, but not
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knees were apparent. Biopsies from region 1, patient 22,
were susceptible to the effects of IL-1, but not TNF,
whereas biopsies from the same region in patient 20 were
susceptible to the effects of TNF, not IL-1. In all, four of
24 regions examined (17%) were susceptible to the effects
of IL-1, while five of 24 (21%) responded to TNF.
However, only biopsies from one of those regions (region 3,
patient 22) were responsive to both IL-1 and TNF.
Overall, biopsies from 47 regions on 10 knees were
examined for susceptibility to the effects of IL-1 and/or
TNF. Biopsies from 10 of the regions (21%) responded to
IL-1, and six (13%) responded to TNF. There was no
significant difference in the number of regions responding
to IL-1 when compared with those responding to TNF
(P=0.411). By contrast, a significantly lower (P<0.047)
number of regions (2/47, 4%) responded to both IL-1 and
TNF.Table II
Comparison of the effects of TNF and IL-1 on cartilage biopsies from the same regions of osteoarthritic knee joints
Cytokine
(pg/ml)
Patient Region 1 Region 2 Region 3 Region 4 Region 5 Region 6 Positive/total*
Regime A
TNF (500) 13 − − − ND − 0/4
IL-1 (10) 13 − − − ND ND − 0/4
TNF (500) 14 − − + − − ND 1/5
IL-1 (10) 14 + − + − − ND 2/5
TNF (500) 15 ND − − − ND ND 0/3
IL-1 (10) 15 ND − + − ND ND 1/3
TNF (500) 16 − − ND − − − 0/5
IL-1 (10) 16 − + ND − − − 1/5
TNF (500) 17 − − − − − − 0/6
IL-1 (10) 17 − − + − − + 2/6
TNF 1/23 (4%)
IL-1 6/23 (26%)
Regime B
TNF (5000) 18 − − − + − − 1/6
IL-1 (10) 18 − − − − + − 1/6
TNF (5000) 19 − − − − ND − 0/5
IL-1 (10) 19 − − − + ND − 1/5
TNF (5000) 20 + + − ND ND − 2/4
IL-1 (10) 20 − − − ND ND − 0/4
TNF (5000) 21 − − − − ND ND 0/4
IL-1 (10) 21 − − − − ND ND 0/4
TNF (5000) 22 − − + ND + − 2/5
IL-1 (10) 22 + − + ND − − 2/5
TNF 5/24 (21%)
IL-1 4/24 (17%)
Total TNF 1/9 1/10 2/9 1/7 1/5 0/7 6/47 (13%)
Total IL-1 2/9 1/10 4/9 1/7 1/5 1/7 10/47 (21%)
Cartilage was obtained from specific anatomical regions on the femoral condyles of 10 osteoarthritic knee joints. Biopsies from five knees,
in replicates of four or more, were incubated for 14 days with IL- (10 pg/ml) or TNF (500 pg/ml) or culture medium (Regime A); biopsies
from a further five knees were incubated with IL-1 (10 pg/ml) or TNF (5000 pg/ml) or culture medium (Regime B). Cumulative GAG release
into supernatants during the incubation period was assessed. Comparison was made between GAG release from biopsies incubated in the
presence of cytokine and that released from biopsies incubated in medium alone. (+) denotes regions where cumulative GAG release from
biopsy halves during incubation with cytokine was significantly greater (P<0.05, Student’s paired t-test) than corresponding control halves
incubated in medium alone, (−) denotes regions where cumulative GAG release during incubation with cytokine was not significantly different
to that from corresponding control halves incubated in medium alone. ND (not done) denotes regions for which insufficient cartilage was
available to make replicate biopsies. *Denotes the number of regions responding to cytokine/total number of regions tested. No significant
difference (P=0.411, Fisher’s exact test) was observed between those regions responding to IL-1 and those responding to TNF.
Significantly fewer (P<0.047, Chi square test) regions responded to both IL-1 and TNF.Discussion
These results show for the first time that the susceptibil-
ity of cartilage biopsies from different anatomical locationson knee joints of OA patients varies in response to the low
amounts of IL-1 found in osteoarthritic joints, as judged by
GAG release. Moreover, the results show variation in
susceptibility to 1, 5 and 10pg/ml IL-1 at different locations
within the same knee joint, as well as at the same location
in different knees. Thus these findings provide an explana-
tion as to how IL-1 produced by the synovium8,15,17 could
contribute to focal loss of cartilage in OA: cartilage loss will
only occur at those locations susceptible to the effects of
IL-1.
It could be argued, however, that the results obtained
may be influenced by the amount of cartilage remaining on
osteoarthritic joints. It is known that the superficial layers of
normal human articular cartilage are more susceptible to
the effects of IL-1 than deeper layers18. As cartilage at the
articulating surface is often missing or damaged in OA
joints, the regional variation in susceptibility to IL-1 could
be attributed to differences between specimens in depth
of cartilage. To preclude this possibility, fibrillated or
damaged cartilage was excluded and only full depth
macroscopically normal cartilage used to make biopsies for
these experiments.
For IL-1 to contribute to focal loss of cartilage, it would
be predicted that biopsies made from cartilage obtained
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the effects of this cytokine than those obtained from distant
sites. However, a minimum of four 3 mm diameter biopsies
of full depth cartilage was required from each of the regions
sampled (Fig. 1), to allow appropriate statistical analysis of
the results. Consequently, insufficient full depth cartilage
was available from sites immediately adjacent to lesions to
compare susceptibility to IL-1 with that from more distal
biopsies. Shlopov et al. (2000)19, however, showed that
chondrocytes proximal to OA lesions are able to bind more
IL-1 and TNF than those at distal sites. These findings
suggest expression of receptors for both catabolic
cytokines is enhanced on chondrocytes at locations adja-
cent to damage as compared with those in cartilage else-
where in the same joint. These observations add credence
to our results showing variation in the susceptibility of
biopsies to the effects of IL-1, which were similar to those
reported for TNF14. Moreover, they emphasize that pre-
disposition to cytokine induced damage may not be uniform
across the joint surface.
Previous work shows signalling for TNF-mediated GAG
release occurs through TNFR-I12. As IL-1RII is suggested
to be a ‘decoy receptor’20, presumably IL-1 mediated
GAG release occurs through IL-1RI. Molecules produced
within the joint, such as IL-1 and IL-6 can up-regulate
chondrocyte TNFR-I expression17, whereas IL-1RI expres-
sion is up-regulated by basic fibroblast growth factor21. It
would therefore be expected that the net effect, in vivo, of
joint fluids that contain a mixture of cytokines would be
up-regulation of the chondrocyte signalling receptors for
both IL-1 and TNF. The results do not support this
postulate. Cartilage from different regions of osteoarthritic
knee joints appears responsive to either, but not usually
both cytokines. These data therefore imply that, ex vivo at
least, the factors affecting the response to TNF or IL-1,
such as expression of IL-1RI and TNFRI, are not usually
up-regulated together.
IL-1 is generally accepted to be the major cartilage
catabolic cytokine. However, this assumption may not be
entirely justified. Cartilage from 21% of the regions tested
responded to IL-1 while 13% responded to TNF. From
these results it would appear that TNF can also contribute
to cartilage destruction. Interestingly, chondrocytes staining
for both IL-1 and TNF have recently been identified in
most osteoarthritic, but not normal, cartilage22.
However, cartilage biopsies from some patients were not
responsive to either IL-1 or TNF. This observation sug-
gests the number of functional signaling receptors for IL-1
and TNF on chondrocytes were insufficient to initiate a
response to either cytokine. Alternatively, in some cartilage
the local concentrations of soluble receptors or other
inhibitors such as interleukin-1 receptor antagonist
protein (IRAP) or tissue inhibitor of metalloproteinase
(TIMPs), may be sufficient to negate the effects of either or
both cytokines. For example, elevated concentrations of
TIMP-3, expressed in human osteoarthritic synoviocytes23,
can prevent the activity of aggrecanases and MMPs as well
as inhibit TNF release24. A further explanation could be that
cartilage in some patients might be responsive to other
cytokines implicated in joint destruction in OA. Recent work
in our laboratory supports this notion. Supernatants from
cultured osteoarthritic synovia15 induced degradation of
osteoarthritic cartilage biopsies. However, attempts to
neutralize the effects of IL-1 and TNF-containing
synovium supernatants with antibodies to either or
both cytokines were not always successful (Westacott,
unpublished observations).Overall, the results presented here support the notion
that IL-1 can contribute to the processes leading to focal
loss of cartilage in OA. Moreover, they highlight differing
sensitivities within and between joints to the two major
catabolic cytokines, IL-1 and TNF, and also imply that in
some patients different catabolic stimuli may predominate.
Such information could be of importance in development of
pharmacological intervention strategies.References
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